Table 1.
Patient and tumor characteristics
| N = 13 | % | |
|---|---|---|
| Age (years) | ||
| Median (range) | 40 (14–64) | |
| Gender | ||
| Male | 9 | 69 |
| Female | 4 | 31 |
| Initial surgery | ||
| Biopsy | 2 | 15 |
| STR | 4 | 31 |
| GTR | 7 | 54 |
| Initial histology | ||
| Glioblastoma, NOS | 3 | 23 |
| Glioblastoma, IDH wild type | 3 | 23 |
| Glioblastoma, IDH mutant | 1 | 8 |
| Diffuse astrotycoma, IDH mutant | 1 | 8 |
| Anaplastic astrocytoma, IDH wild type | 1 | 8 |
| Anaplastic astrocytoma, IDH mutant | 2 | 15 |
| Anaplastic oligodendroglioma, NOS | 1 | 8 |
| Pleomorphic xanthoastrocytoma | 1 | 8 |
| Initial grade | ||
| II | 2 | 15 |
| III | 4 | 31 |
| IV | 7 | 54 |
| IDH status | ||
| Mutant | 4 | 31 |
| Wild type | 3 | 23 |
| Unknown | 6 | 46 |
| 1p/19q status | ||
| Codeleted | 1 | 8 |
| Single deletion | 1 | 8 |
| Intact | 4 | 31 |
| Unknown | 7 | 54 |
| MGMT status | ||
| Methylated | 1 | 8 |
| Unmethylated | 2 | 15 |
| Unknown | 10 | 77 |
| Initial chemotherapy | ||
| TMZ | 7 | 54 |
| TMZ + dasatinib | 1 | 8 |
| None | 5 | 38 |
| RT delivered | ||
| Yes, initial course | 9 | 69 |
| Yes, recurrence | 2 | 15 |
| No | 2 | 15 |
| Initial RT dose (Gy) | ||
| Median (range) | 59.4 (54–60) | |
| Time to first recurrence (months) | ||
| Median (range) | 25 (6–143) | |
| Time from diagnosis to study enrollment (months) | ||
| Median (range) | 30 (10–247) | |
| Number of recurrences | ||
| 1 | 9 | 69 |
| 2 | 1 | 8 |
| 5 | 2 | 15 |
| 6 | 1 | 8 |
| Prior salvage chemotherapy | ||
| Yes | 3 | 23 |
| No | 10 | 77 |
| Number of salvage chemotherapy courses | ||
| 3 | 2 | 67 |
| 4 | 1 | 33 |
| Salvage chemotherapy agentsa | ||
| TMZ | 5 | 50 |
| CCNU | 2 | 20 |
| PCV | 1 | 10 |
| Bevacizumab | 1 | 10 |
| Prior salvage surgery | ||
| None | 9 | 69 |
| 1 | 1 | 8 |
| 2 | 0 | 0 |
| 3 | 3 | 23 |
| Type of salvage surgeryb | ||
| Biopsy | 1 | 10 |
| STR | 5 | 50 |
| GTR | 4 | 40 |
| Type of study surgery | ||
| Biopsy | 2 | 15 |
| STR | 3 | 23 |
| GTR | 8 | 62 |
| Recurrence gradec | ||
| II | 1 | 8 |
| III | 5 | 38 |
| IV | 7 | 54 |
| Recurrence histologyd | ||
| Astrocytoma | 10 | 77 |
| Oligoastrocytoma | 3 | 23 |
| Oligodendroglioma | 0 | 0 |
STR subtotal resection, GTR gross total resection, IDH isocitrate dehydrogenase, MGMT O-6-methylguanine-DNA-methyltransferase, TMZ temozolomide, CCNU lomustine, PCV procarbacine, cyclophos-phamide, vincristine, RT radiation therapy
a
Denominator is total number of courses of chemotherapy
b
Denominator is total number of surgeries performed
c
The highest grade tissue obtained at the time of study surgery or during any prior procedure
d
Classified using 2007 WHO criteria. Histologic classification using 2016 WHO criteria was not possible due to a lack of mutation status testing performed on recurrent specimens